What does this research mean for the field?

The combination of tiletamine-zolazepam and dexmedetomidine provides a depth of controlled sedation and safety profile comparable to the ketamine-dexmedetomidine regimen in dogs and cats undergoing invasive mechanical ventilation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare the efficacy and safety of tiletamine-zolazepam combined with dexmedetomidine versus ketamine combined with dexmedetomidine for controlled sedation in mechanically ventilated dogs and cats.

August 22, 2026Russian veterinary journal

The efficacy and safety of the combination of tiletamine-zolazepam (Vezotil®) with dexmedetomidine for controlled sedation of dogs and cats during invasive mechanical ventilation: a pilot prospective randomized controlled trial

View Full Paper

Ask AI

Bookmark

Authors

AAAleksandr Arzhaev YIYuliya Ilatovskaya BBBella Babicheva

Discussion

Member takes

Overview

Randomized trial reveals equivalent sedation depth between tiletamine-zolazepam and ketamine in ventilated dogs and cats, suggesting an effective alternative without controlled substances.

Key Points

To compare the efficacy and safety of tiletamine-zolazepam combined with dexmedetomidine versus ketamine combined with dexmedetomidine for controlled sedation in mechanically ventilated dogs and cats.
Conducted a pilot prospective randomized controlled trial in an intensive care unit involving 40 mechanically ventilated patients (23 dogs and 17 cats).
Randomized animals to receive either tiletamine-zolazepam plus dexmedetomidine (TZ+D, n = 20) or ketamine plus dexmedetomidine (K+D, n = 20).
Evaluated sedation depth via the Medication-Controlled Sedation during Mechanical Ventilation (MCS-MV) scale (target 8–10) alongside rescue bolus needs, complications, and unfavorable outcomes.
Sedation depth scores reached target levels in both groups, showing no significant difference (median MCS-MV score: 9.5 in TZ+D vs 9.0 in K+D; Hodges–Lehmann shift estimate 0.0 points, 95% CI −1.0 to +1.0; p = 0.841).
Rescue bolus requirements were similar between the TZ+D and K+D cohorts (median 0.5 vs 2.0 boluses; U = 167.5; p = 0.398).
Complication rates (15.0% vs 10.0%; risk difference +5.0 percentage points, 95% CI −17.3 to +27.2; p = 1.000) and unfavorable outcomes (40.0% vs 30.0%; risk difference +10.0 percentage points, 95% CI −18.4 to +36.3; p = 0.741) did not differ significantly.

Cite This Study

Arzhaev et al. (2026) studied this question.

synapsesocial.com/papers/6a895ffeca7ade938187f01b https://doi.org/10.32416/2500-4379-2026-3-35-43

View Full Paper

Ask AI

Bookmark

August 22, 2026Russian veterinary journal

The efficacy and safety of the combination of tiletamine-zolazepam (Vezotil®) with dexmedetomidine for controlled sedation of dogs and cats during invasive mechanical ventilation: a pilot prospective randomized controlled trial

View Full Paper

Ask AI

Bookmark

Authors

AAAleksandr Arzhaev YIYuliya Ilatovskaya BBBella Babicheva

Discussion

Member takes

Overview

Randomized trial reveals equivalent sedation depth between tiletamine-zolazepam and ketamine in ventilated dogs and cats, suggesting an effective alternative without controlled substances.

Key Points

To compare the efficacy and safety of tiletamine-zolazepam combined with dexmedetomidine versus ketamine combined with dexmedetomidine for controlled sedation in mechanically ventilated dogs and cats.
Conducted a pilot prospective randomized controlled trial in an intensive care unit involving 40 mechanically ventilated patients (23 dogs and 17 cats).
Randomized animals to receive either tiletamine-zolazepam plus dexmedetomidine (TZ+D, n = 20) or ketamine plus dexmedetomidine (K+D, n = 20).
Evaluated sedation depth via the Medication-Controlled Sedation during Mechanical Ventilation (MCS-MV) scale (target 8–10) alongside rescue bolus needs, complications, and unfavorable outcomes.
Sedation depth scores reached target levels in both groups, showing no significant difference (median MCS-MV score: 9.5 in TZ+D vs 9.0 in K+D; Hodges–Lehmann shift estimate 0.0 points, 95% CI −1.0 to +1.0; p = 0.841).
Rescue bolus requirements were similar between the TZ+D and K+D cohorts (median 0.5 vs 2.0 boluses; U = 167.5; p = 0.398).
Complication rates (15.0% vs 10.0%; risk difference +5.0 percentage points, 95% CI −17.3 to +27.2; p = 1.000) and unfavorable outcomes (40.0% vs 30.0%; risk difference +10.0 percentage points, 95% CI −18.4 to +36.3; p = 0.741) did not differ significantly.

Cite This Study

Arzhaev et al. (2026) studied this question.

synapsesocial.com/papers/6a895ffeca7ade938187f01b https://doi.org/10.32416/2500-4379-2026-3-35-43

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark